COVID-19 restrictions to remain in place at The Walton Centre

Restrictions remain in place across the NHS in relation to the COVID-19 pandemic. The safety measures in place over the 18 months therefore remain in place at The Walton Centre - and in our other clinic settings within the community – until further notice.

Due to the increased transmission risk posed by the Omicron variant, visiting has been suspended within The Walton Centre except for exceptional circumstances.

Dr Saif Huda

About Saif Huda

Dr Saif Huda completed undergraduate medical training in Liverpool in 2005 and completed neurology specialist training at The Walton Centre in 2017. Between 2012-2015 he undertook a DPhil in neuroimmunology at The University of Oxford before completing a post-CCT fellowship in neuromyelitis optica in 2018.  

Dr Huda is the clinical lead for the UK NMOSD highly specialised service. My team and I provide a multidisciplinary service for patients with NMOSD and myelin oligodendrocyte glycoprotein associated disease (MOGAD) across the United Kingdom. I am also a Multiple Sclerosis specialist and have expertise in antibody-mediated central nervous system disorders.  

He provides a weekly MS clinic and acute ward referral service to Glan Clywd Hospital, North Wales.  In addition to general neurology clinics he also holds a monthly CNS autoimmune clinic.  

Dr Huda’s group’s research focuses on immune tolerance mechanisms and biomarkers in NMOSD and MOG-antibody associated disease, particularly clinical and serological biomarkers that help predict relapse risk and prognosis. They are also interested in immune tolerance mechanisms and identifying novel symptomatic therapies that can improve patient quality of life. Dr Huda is a principal investigator for several Phase III clinical trials in NMOSD, MOGAD, and autoimmune encephalitis.      


Neuromyelitis optica spectrum disorders (NMOSD) 

Multiple sclerosis (MS) 

Antibody-mediated CNS disease 

Myasthenia gravis  





Clinical/research interests


Neuromyelitis optica spectrum disorder (NMOSD) 

Myelin oligodendrocyte glycoprotein associated disease (MOGAD) 

Multiple Sclerosis 

Antibody-mediated central nervous system disorders 


NMOSD and MOGAD - clinical and serological biomarkers that help predict relapse risk and prognosis 

Immune tolerance mechanisms and identifying novel symptomatic therapies that can improve patient quality of life 

Autoimmune encephalitis    

Membership of professional regional and national bodies

Royal College of Physicians London 

Association of British Neurologists 

American Academy of Neurology 

Related Services


The Neurology service provides specialist care to patients across Cheshire, Merseyside, North Wales and the Isle of Man. 

Multiple sclerosis

Multiple Sclerosis (MS) is the most common potentially disabling disease of the central nervous system affecting young adults.

Page last updated: 14 July 2021